Invivyd Announced That The First Participant Has Been Dosed In CANOPY Phase 3 Trial Of Vyd222, A Monoclonal Antibody, For The Prevention Of Symptomatic Covid-19 Canopy Is Expected To Enroll Approximately 750 Patients
Portfolio Pulse from Benzinga Newsdesk
Invivyd has announced the dosing of the first participant in its CANOPY Phase 3 trial of Vyd222, a monoclonal antibody for the prevention of symptomatic Covid-19. The trial is expected to enroll approximately 750 patients.
September 11, 2023 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Invivyd's announcement of the first dosing in its Phase 3 trial of Vyd222 could potentially boost investor confidence in the company's Covid-19 prevention efforts.
The initiation of Phase 3 trials is a significant milestone in drug development, indicating that the drug has shown promise in earlier stages. This news could potentially boost investor confidence in Invivyd's ability to develop a successful Covid-19 prevention treatment, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100